---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000167"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:48:39.323671+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD

## Summary
- Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.
- Primary objective: evaluate safety and tolerability; secondary: blood pressure reduction and pharmacokinetics.
- IND review takes minimum 30 days; trial start subject to FDA effectiveness and funding.
- This marks formal regulatory scrutiny toward pharmaceutical commercial registration for DehydraTECH technology.

## SEC filing metadata
- accession: 0001640334-24-000167
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000167/0001640334-24-000167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000167/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000167
- JSON: https://secwatch.observer/filing/0001640334-24-000167.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.